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Background: Both yaws and trachoma are endemic in several countries in the Paciﬁc. In co-endemic countries
there may be potential synergies between both control programmes.
Methods: We undertook a cluster randomised trachoma and yaws seroprevalence survey of children in the
Western Division of Fiji. Children were examined for skin lesions consistent with active yaws. A dried blood
spot was collected which was tested using the Treponema pallidum particle agglutination (TPPA) test and an
ELISA to detect antibodies against Pgp3.
Results: A total of 607 children from 305 households across 23 villages were recruited into the survey. On skin
examination, no child had clinical evidence of yaws, and the TPPA assay was negative in all children (0%, 95%
CI 0.0–0.6). The seroprevalence of Pgp3 antibodies was 20.9% (95% CI 17.8–24.6%).
Discussion: In this study there was neither clinical nor serological evidence that transmission of yaws was
ongoing. The Pgp3 seroprevalence pattern was consistent with either low level transmission of ocular
Chlamydia trachomatis or exposure to C. trachomatis in the birth canal which is consistent with a survey con-
ducted in the same region in 2013. These data suggest neither yaws nor ocular chlamydia infection are a sig-
niﬁcant public health problem in the Western Division of Fiji.
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Introduction
Yaws, caused by Treponema pallidum subsp. pertenue, is
endemic in several countries in the Paciﬁc.1 Trachoma, caused
by ocular infection with Chlamydia trachomatis, is the leading
infectious cause of blindness and is also endemic in the
Paciﬁc.2,3 Both diseases are classiﬁed as neglected tropical dis-
eases (NTDs) by WHO. WHO has targets for both the global
eradication of yaws and elimination of blinding trachoma as a
public health problem by 2020.4,5 Central to the strategy for
both of these targets is the use of community mass treatment
with azithromycin, which is an effective therapy for both
organisms. In countries where both yaws and trachoma are
endemic there may be potential synergies between the control
programmes at multiple levels including survey, intervention
and surveillance.6,7
Of the countries where yaws remains endemic, three of the
most high-burden countries are in the Paciﬁc, including Papua
New Guinea, the Solomon Islands and Vanuatu.8 Yaws has pre-
viously been reported in many other countries in the Paciﬁc,
including Fiji, but there are no current data from Fiji on the
prevalence of active disease or the seroprevalence of infection.9
Accurate data on both clinical and serological prevalence of
yaws in Fiji are needed to guide programmatic decision making.
Trachoma has been reported to be endemic in a number of
countries in the Paciﬁc, although population-based mapping
studies have suggested a relatively low number of cases of
trichiasis the late, blinding, stage of the disease – in the
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region. A recent survey completed in the Western Division of
Fiji reported a low prevalence of ocular infection with C. tra-
chomatis among children, and similar ﬁndings have been
reported from other Paciﬁc countries, including the Solomon
Islands.10
Serology has recently emerged as a potential surveillance
tool for trachoma programmes. Current measures of ocular
infection (directly by PCR, or indirectly by clinical examination)
provide only a cross-sectional snapshot of community preva-
lence, without necessarily giving any information about the
changing exposure in a population over time. For trachoma,
antibodies to Pgp3 are thought to be a long-lived and speciﬁc
marker for prior C. trachomatis exposure.11,12 Serology is also a
major tool in surveillance for yaws. Treponemal antibodies per-
sist for life and cannot distinguish between yaws and syphilis.
A prevalence of treponemal antibodies greater than 1% amo-
ngst children has been suggested as a possible trigger for more
detailed yaws mapping studies.13
The collection of dried blood spot samples in prevalence
surveys have recently emerged as a practical tool to allow col-
lection and storage of a large number of ﬁnger-prick blood
samples from which the seroprevalence of several infections
can be assessed. This has notable advantages in facilitating
integrated NTD mapping and surveillance activities.14,15 Prior
to this study implementation of the SAFE strategy for elimin-
ation of trachoma had not yet commenced in Fiji and there
had not been any azithromycin mass drug administration con-
ducted in the country. We conducted an integrated survey to
assess the seroprevalence of antibodies to T. pallidum and
C. trachomatis in order to evaluate the need for further inter-
ventions for these NTDs in Fiji.
Methods
We conducted a population-based cluster-randomised sur-
vey in the Western Division of Fiji in July and August 2015,
where we had previously documented a low prevalence of
both clinical signs of active and ocular infection with C. tra-
chomatis.2 No mass distribution of azithromycin for trach-
oma or yaws has previously been carried out in this region,
nor any recent penicillin-based mass treatment campaigns
for yaws, to the best of the authors’ knowledge. Data are
reported in line with the STROBE guidelines for cross-
sectional surveys (Supplementary File 1). Study data are
available in Supplementary File 2.
Survey methodology
This was a two-stage cluster-randomised survey. Each cluster
consisted of a single village. Villages were selected randomly,
using probability proportional to size sampling, from a list of all
communities in the Western Division of Fiji. On the day on the
survey, in collaboration with local leaders, a list of all households
was enumerated and 30 households selected using simple ran-
dom sampling. All children aged 1–14 at sampled households
were eligible for inclusion.
Data collection
A nurse was trained in standardised dermatology. Examinations
included the head and neck, limbs and trunk but excluded the
genitals and buttocks. Individual-level data were collected on
age, gender, and the presence or absence of skin lesions. For
each skin lesion we recorded the location, clinical appearance
and whether the lesion was consistent with yaws or an alterna-
tive diagnosis. A clinical case of yaws was deﬁned on the basis
of typical clinical ﬁndings of papillomatous or chronic, painless
ulcerative skin lesions and using the WHO pictorial guide to
yaws.16 The clinical diagnosis of scabies was based on features
including morphology (burrows, papules, nodules, vesicles) and
body distribution of rash; presence of pruritus on history or evi-
dence of excoriation; contact history with individuals with a
similar rash and itch; and consideration of differential diagnoses.
The distribution of scabies lesions was noted using nine pre-deﬁned
body regions. Scabies severity was classiﬁed by the number of
lesions present as mild (≤10 lesions), moderate (11–49 lesions)
or severe (≥50 lesions or crusted scabies).
Active impetigo was diagnosed on the basis of discrete papu-
lar, pustular or ulcerative lesions with associated erythema,
crusting, bullae or frank pus. Inactive impetigo was diagnosed
by the presence of discrete, non-conﬂuent healed superﬁcial
skin lesions. Severity of active impetigo was classiﬁed as very
mild (≤5 lesions), mild (6–10 lesions), moderate (11–49 lesions)
or severe (≥50 lesions).
All data were entered directly into Android smartphones
using the OpenDataKit software package.17 Individuals with a
skin condition requiring treatment were referred to the local
health clinic where they were treated free of charge in line with
Ministry of Health guidelines.
A ﬁnger-prick blood sample was collected onto a ﬁlter paper
from all children regardless of clinical features. Filter papers were
air-dried and stored in a sealed bag with a desiccant sachet. In
individuals with ulcerative or papillomatous skin lesions consist-
ent with yaws we also collected a swab sample of lesion exud-
ate. Exudate was transferred to a FTA Elute Micro Card (GE
Healthcare, Chalfont St Giles, UK) using three ﬁrm side-to-side
motions of the swab across the card. Each card was placed in its
own re-sealable plastic packet with an individual desiccant
sachet. All samples were transferred to Lautoka Hospital and fro-
zen at −20°C and then shipped to the London School of Hygiene
& Tropical Medicine (LSHTM), London, UK for testing.
Laboratory testing
Blood samples were tested at LSHTM. All laboratory testing was
performed by individuals masked to the clinical ﬁndings. For
yaws, a single extension of each ﬁlter paper sample was eluted
as previously described and the elute tested using the T. pallidum
particle agglutination test (TPPA; Mast Diagnostics, Bootle, UK).18
For trachoma, a separate extension of each ﬁlter paper was
tested using an ELISA for Pgp3 developed by the US Centres for
Disease Control (Diana Martin, personal communication). Dried
blood spots were eluted into 250 µL of 1× phosphate-buffered
saline (PBS) with 2.5% weight-for-volume milk powder plus 0.3%
volume-for-volume tween 20 (PBST-milk). Immunolon 2HB plates
were coated overnight with 50 ng per well glutathione S-transferase
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(GST)-tagged Pgp3 then blocked for 1 hour with PBST. Plates
were bound for 2 hours with 50 µL of the elution mixture, then
incubated at room temperature with rabbit anti-IgG for 1 hour.
Plates were then incubated in the dark for 10 minutes with tetra-
methylbenzidine (TMB) and the absorbance read at 450 nm. Plates
were washed four times with PBST between steps. A series of posi-
tive serum diluted in negative serum was run on each plate. Plates
were re-run if the mean of each point in the dilution series fell
more than 20% outside of pre-determined normal range. All
specimens on the plate were normalised to a 20% dilution of
presumed-positive material as that typically gave optical density
(OD) readings around 1.
Statistical analysis
We calculated the clinical prevalence of yaws and other com-
mon skin infections. A positive cut-off value for the Pgp3 ELISA
was deﬁned using a mixtures model.19 For the purposes of ana-
lysis we grouped age into 1–5 years, 6–10 years and 11–14
years of age. We categorised ethnicity as iTaukei, Indo-Fijian
(the predominant ethnic groups in Fiji) or other. We calculated
the seroprevalence of antibodies against T. pallidum and C. tra-
chomatis. Random effects logistic regression was used to assess
associations between age, sex, ethnicity and gender with both
clinical ﬁndings and seroprevalence data controlling for the
effect of clustering at household and village-level. Analysis was
conducted in STATA 13.1 (StataCorp LP, College Station, TX, USA)
and R 3.2.3 (the R Project for Statistical Computing).20
Sample size
We calculated that a sample size of 1005 children was needed
to detect a seroprevalence of both treponemal antibodies and
Pgp3 antibodies of 5% in 1–14 year-olds with a degree of preci-
sion of ±2%, a design effect of 2, and a 10% non-response rate.
Based on the Fiji national census we calculated that 30 house-
holds in each of 30 villages would be sufﬁcient to reach this
sample size.
Ethical approval
Written informed consent was obtained from each participating
child’s parent or guardian by a member of staff ﬂuent in the
local dialect. Assent was obtained from all children with a signa-
ture or thumb print. Ethical approval for the study was granted
by the ethics committees of the Fiji Ministry of Health (2015.65.
WES) and LSHTM (10359).
Results
A total of 607 children from 305 households across 23 villages
were recruited into the survey. The median age was 6 years
(IQR 4–9), 312 children were male (51.4%). There were 493
individuals of iTaukei descent (81.2%), 91 individuals were
Indo-Fijian (15.0%) and 23 children were of another ethnicity
(3.8%).
On examination 184 children (30.3%) had at least one skin
lesion. No skin lesions were considered to be clinically consistent
with yaws. The most common skin lesions noted were scabies
without secondary bacterial infection (n=59, 9.7%), scabies with
bacterial skin infection (n=31, 5.1%) and impetigo without
underlying scabies (n=24, 3.9%). Scabies was more common
amongst children of iTaukei ethnicity (OR 2.9, p=0.015) and was
the major risk factor for the presence of impetigo (OR 10.30,
p<0.0001) with a population attributable fraction of 51.2%.
Eczema (n=18, 2.9%), tinea corporis (n=16, 2.6%) and mollus-
cum contagiosum (n=14, 2.3%) were also common (Figure 1).
Dried blood spots were collected from 593 children (96.7%).
The TPPA was negative in all children enrolled in this study (95%
CI 0–0.6%). Because no yaws-like lesions were identiﬁed no
swabs for PCR were collected. Using the mixtures model an OD
threshold of 0.72 was deﬁned for the Pgp3 assay. Based on this
cut-off the overall seroprevalence of Pgp3 antibodies was
20.9%. Seroprevalence increased with age from 15% in children
aged 1 year to 22% amongst children aged 14 years. In univari-
ate analysis both age and ethnicity were signiﬁcantly associated
with a positive Pgp3 ELISA (p=0.043 and p<0.001 respectively)
but there was no association with gender (p=0.71). In multivari-
able analysis iTaukei ethnicity was associated with a signiﬁ-
cantly increased risk of Pgp3 seropositivity (aOR 9.82, 95% CI
2.94–32.79, p<0.001) (Table 1 and Figure 2).
Discussion
We found no evidence that yaws was still endemic in the
Western Division of Fiji. No children were identiﬁed with clinical
evidence of yaws and treponemal antibody testing was nega-
tive in all children. As these tests reﬂect lifetime exposure to
T. pallidum this represents strong evidence that transmission of
yaws is not ongoing in the communities where this study took
place. Approximately one-ﬁfth of children in the study had evi-
dence of exposure to C. trachomatis. In a previous study in the
Western Division of Fiji we reported a trachomatous inﬂamma-
tion – follicular (TF) prevalence of 2.8% and an ocular chlamydia
infection prevalence of 2.3%.2 These serology data are compar-
able to other settings where there is a low prevalence of both TF
and ocular chlamydia infection.21 Steeply increasing age-speciﬁc
anti-pgp3 prevalence in children aged between 1 and 10 years
is thought to be indicative of intense transmission of ocular
Figure 1. Clinical prevalence of common skin infections.
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C. trachomatis; in this population the prevalence of anti-pgp3
antibodies was already high in the 1-year age group, suggesting
the majority of seropositivity was acquired at in the ﬁrst year of
life.12,21 As Pgp3 is conserved between urogenital and ocular
strains of C. trachomatis we cannot discount the possibility that
the Pgp3 seroprevalence may reﬂect transmission in the birth
canal as well as, or indeed more than, ocular transmission of
chlamydia. The prevalence of urogenital C. trachomatis infection
amongst pregnant women has previously been reported to be
high in Fiji and community prevalence surveys in other Paciﬁc
countries have also reported high rates of urogenital C. tracho-
matis.22,23 In a study of pregnant women in Suva, Fiji, native
Fijian women were found to have higher rates of urogenital
infections, including C. trachomatis, than Indo-Fijian women.24
Based on the current data it is unclear whether ocular C. tracho-
matis infection or transmission in the birth canal is the major
driver of Pgp3 seropositivity in these communities. These data
highlight the potential challenges of using Pgp3 as a sero-marker
for trachoma in communities where the prevalence of genital
chlamydia infection is also high.
Skin problems were common in this study population with
scabies and impetigo the most commonly identiﬁed conditions.
These ﬁndings are consistent with a national scabies prevalence
survey that was previously conducted in Fiji.25 As previously
noted scabies was more common amongst iTaukei than indo-
Fijians and was the major risk factor for impetigo.25 The absence
of both chronic ulcerative lesions and papillomatous lesions
consistent with yaws is supported by our serological data show-
ing an absence of treponemal antibody positivity. Anecdotally,
health care staff in the Western Division of Fiji reported that
they did not see children with skin lesions consistent with yaws
presenting to health care clinics.
Our study has a number of limitations. Whilst survey clusters
were chosen in advance, we did not achieve our desired sample
size because of logistical difﬁculties on the days of surveys of
particular communities and the time limitations of the survey
team. This may have limited our ability to detect rare cases of
yaws amongst these communities. This is of particular import-
ance as yaws is known to be highly focal even in regions where
it is endemic. However the absence of any positive treponemal
antibody tests in children enrolled in this study provides strong
evidence that transmission is not ongoing in the communities
included in this study. The appropriate methodology for conﬁrm-
ing yaws elimination has not yet been agreed but it is likely that
large-scale seroprevalence surveys will be required. The reduced
sample size also reduced the statistical power to assess asso-
ciations between demographic variables and Pgp3 antibody sta-
tus. Secondly, the study was conducted in only a limited
geographic region of Fiji. Further studies in other parts of the
country should be undertaken. Finally we did not collect linked
clinical data on active trachoma or ocular swabs for PCR during
this survey. We had conducted a previous survey in this region of
Fiji two years earlier where we have demonstrated a low preva-
lence of TF (2.8%) and ocular C. trachomatis infection (2.3%)
Table 1. Factors associated with Pgp3 antibody positivity
Variable Indicative prevalence data Adjusted odds ratioa (95% CI) p-valueb
Age (years)
1–5 (n=267) 16.9% 1 p=0.0133
6–10 (n=218) 23.3% 1.83 (1.10–3.02)
11–14 (n=99) 25.2% 2.20 (1.17–4.15)
Ethnicity
Indo–Fijian (n=86) 3.5% 1 p<0.0001
iTaukei (n=476) 24.8% 10.88 (3.12–37.92)
Other (n=22) 9.1% 2.89 (0.39–21.05)
Gender
Male (n=308) 20.5% 1 NS
Female (n=276) 21.7% 0.89 (0.57–1.38)
NS: not signiﬁcant.
a All odds ratios are adjusted for age, gender and ethnicity.
b Likelihood ratio test.
Figure 2. Seroprevalence of Pgp3 antibodies by age and ethnicity. Data
are seroprevalence and 95% CIs. Only data for iTaukei and Indo-Fijian
children are shown due to the small number of children of other
ethnicities.
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amongst children2 and where no cases of trachomatous tricha-
sis were seen.
There is a need for better data to inform programmatic decision
making and integrated approaches to NTDs in the Paciﬁc. Our study
has conﬁrmed that yaws and trachoma mapping activities can be
integrated and that it may be possible to expand this to other NTDs
such as scabies. There is also scope for cooperation between mass
treatment programs, for example co-administration of ivermectin,
albendazole and azithromycin, where more than one treatment is
indicated and appropriate safety and efﬁcacy data exist.26 Our data
add to existing data suggesting that yaws is no longer a public health
problem in Fiji and that trachoma is not likely to be one of the major
causes of blindness in Fiji. Given the mixed ﬁndings of trachoma sur-
veys conducted in Fiji early impact assessments should be conducted
to guide Ministry of Health trachoma elimination activities.
Supplementary data
Supplementary data are available at Transactions online
(http://trstmh.oxfordjournals.org/).
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